Across TCGA pan-cancer cohorts, AADACL3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AADACL3 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher AADACL3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AADACL3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

PAAD, PRAD, and BLCA are the cancer types where AADACL3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	DFS	Median	All	0.112	0.484	.015	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	OS	Median	All	0.210	0.618	.021	6	view →
LUAD	OS	Median	III,IV	0.068	0.680	<.001	6	view →
UCEC	DFS	Median	All	1.000	0.625	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: AADACL3 tumor-vs-normal RNA expression · all AADACL3 data types